Efficacy of Arq-e-Zeera and Qurs-e-Tabasheer in the Secondary Prevention of Metabolic Syndrome: An Open Intervention Study

The metabolic syndrome (MetS) consists of a constellation of metabolic abnormalities that confer an increased risk of cardiovascular disease (CVD) and diabetes mellitus and it has gained significant interest worldwide due to its escalating prevalence, which places a heavy burden on the global healthcare system. According to IDF & AHA/NHLBI (2009) criteria, A person to be diagnosed with MetS, he/she should have 3 or more of the 5 components of MetS. They are: central obesity, hypertriglyceridemia, low HDL-C, hypertension and hyperglycemia.

The MetS hasn’t been described in Unani classical literature. But, according to Unani physicians, the key risk factors of MetS i.e. diabetes mellitus, obesity, high blood pressure and abnormal blood lipids have been described separately as different disease conditions. There are several single and compound drugs have been mentioned in Unani classical texts to treat each component of MetS separately. But as a syndrome its components vary from person to person. Therefore it is aimed to select Arq- e-Zeera and Qurs-e- Tabasheer in combination to evaluate their combined effect in the secondary prevention of Metabolic syndrome.

Clinically knownand newlydiagnosed cases of MetS, if fulfilling selection criteria will be selected and enrolled after obtaining written informed consent. Subjects will be administered with  75 ml of Arq-e-Zeera twice a day before meals and 3 Tablets of Qurs-e-Tabasheer twice a day after meals for 60 days. Followup will be done on 0th, 15th, 30th, 45th and 60th days. Baseline examination and 60th day examination will be analyzed statistically. The data on objective parameters will be recorded in a specialized case report form (CRF). Outcome of the study will be compared with the findings of baseline and after completion of the study.